Contact: NCI Press Office
Conference participants will consider new information on chemotherapy, hormonal
therapy, and other aspects of treatment that have emerged in recent years. Like other
NIH consensus conferences, the meeting will culminate in recommendations for clinical
“A substantial amount of new data has become available since the last consensus
conference in 1990,” said Jeff Abrams, M.D., of the National Cancer Institute’s
(NCI’s) Cancer Therapy Evaluation Program, which is organizing the meeting. “NIH
decided the time was ripe
for another consensus conference because studies in the last decade have raised issues
that need to be factor
ed into treatment decisions.”
During the conference, a panel of experts from outside NIH will hear presentations
from leading researchers and then consider questions on specific topics, such as the
selection of chemotherapy, radiation, and hormonal therapy. The agenda, now under
development, will also include the clinical use of prognostic markers and quality-of-life
issues. The conference will cover both node-negative and node-positive breast cancer.
Media may register for the conference by calling Caroline McNeil at the NCI press
office at (301) 496-6641. Health professionals, researchers, patient advocates, and
other members of the public may register by sending an e-mail to
email@example.com by going to the NIH Web site for consensus
conferences at http://odp.od.nih.gov/consensus. Additional information is available by
calling (301) 592-3320.
For more information about cancer visit NCI's Web site for patients, public, and the
mass media at http://www.nci.nih.gov.